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I read with interest the article by Jantikar et al.1 that was
published in the April 2007 edition of Respiratory Medicine,
which reported similar bronchodilator response between
200mg of salbutamol and 100mg of levosalbutamol. A sensitive
comparison on the bronchodilator effect of salbutamol and
levosalbutamol ((R)-salbutamol) would have been useful to
clarify the controversy regarding the clinical relevance of the
preclinical and in vitro negative effects of dextrosalbutamol
((S)-salbutamol).2,3 However, in order to avoid the constant
repetition of the same methodological deficiencies, I believe
that it is important to highlight these flaws that invalidate the
study conclusions and, therefore, do not provide relevant
information to the controversy, like many other manuscripts
before, as it was already highlighted by Ahrens and
Weinberger.4 Even the paper by Lotvall et al.5 that seemed
to be sensitive according to Ahrens and Weinberger, has to be
questioned according to Fishwick et al.6
In the paper by Jantikar et al. we can find three major
deficiencies.
Firstly, it is well known that the comparison of the
bronchodilating or bronchoprotective effect of b2-agonists
has to be performed with at least two doses of each product to
calculate a simple dose–response curve for each product,7
which indicates if the study presents assay sensitivity to
detect differences. In addition, the comparison is not based
on the response obtained with equivalent doses of each
product but on the shift of the dose–response curve of both
products, which is called the relative potency.8 This concept
was applied to the comparison of inhalation products more
than 30 years ago9–11 and has been incorporated into the
requirements of the Regulatory Agencies to avoid false
conclusions of equivalence due to the flatness of the
dose–response curve of b2-agonists.
12–14 Therefore, it is
surprising that insensitive studies are still being designed by
scientists that should be updated, approved by ethical
committees that should avoid human experimentation without
any usefulness and publication in peer-reviewed journal that
give credibility to insensitive designs and their conclusions.
The sensitivity of this trial could have been investigated
without an increase of complexity. The inclusion ofont matter & 2007 Elsevier Ltd. All rights reserved.
2007.05.013a placebo treatment in the cross-over design is unnecessary
(nice to see but not needed), because there is no doubt that
any dose of salbutamol is going to be superior to placebo.
Placebo is usually required to give internal validity in studies
that investigate drugs that have not shown superiority to
placebo consistently (e.g. topical NSAIDs). The use of
another dose of any active treatment (e.g. 100 mg of
salbutamol or 50 mg of the eutomer) would have been
preferable to provide assay sensitivity since it allows the
estimation of the relative potency (even with methods
different to the Finney bioassay) and demonstrates whether
different doses provide similar responses and, therefore, the
comparison of the responses is insensitive to detect any
difference.
Secondly, this study has compared 200 mg of salbutamol
versus 100 mg of levosalbutamol. It is also known that a
single actuation of 100 mg of salbutamol produces and
increment in FEV1 that is close to peak response in mild-
to-moderate asthmatics.15 Similarly, it has been described
that 40 mg of salbutamol provides 80% of the personal best
value of FEV1.
16 Therefore, the comparison at a dose of
200 mg has been performed at the upper plateau of the
dose–response curve of salbutamol. Then, the study is
insensitive to detect any difference if such a difference
exists.
Thirdly, the authors have always considered that the lack
of statistical significant differences is indicative of similar-
ity. It has to be remembered that absence of evidence (of a
difference) is not evidence of absence (of a difference). In
other words, the inability to reject the null hypothesis does
not support the validity of the null hypothesis. Only the
alternative hypothesis can be proved in a test of hypothesis.
In conclusion, the authors should have employed the
hypothesis of equivalence in the alternative hypothesis.
The authors’ confusion is shown in the wording employed to
justify the sample size calculation. This wording is confusing
because at the same time it claims that 24 subjects were
required to detect differences between study medication
with 80% power (which shows that it is a superiority test)
and to show equivalence at a significance level of 5% (which
seems to be an equivalence test, but no equivalence limits
have been defined). In order to calculate the sample size for
an equivalence test it is necessary to define the acceptance
range (d), the difference expected between treatments (D),
the variability of the response (s), the consumer risk
(a ¼ 5%) and the produce risk (b ¼ 20% to have a power of
80%). The authors only mention that the size estimation was
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following salbutamol administration in a previous study,
which is none of the parameters needed and apparently
irrelevant. This confusion is confirmed with the use of
Student’s t-test for paired variables employed to detect
differences (superiority test) and the Schuirmann’s two one-
sided test of equivalence, which are equivalent to con-
fidence intervals for the ratio or difference. Unfortunately,
no confidence interval is provided and the similarity is
concluded when statistically significant differences are not
detected (P40.05).
Besides these three major deficiencies, other interesting
issues can be identified.
The authors have compared two identical formulations
and devices manufactured by Cipla Ltd. that apparently only
differ in the amount of active substance. This has been
necessary in order to assure that the difference if detected
is not due to the different formulation or device. However,
although unlikely, it should be confirmed that both
formulations show a similar lung deposition by means of,
for example, a pharmacokinetic lung deposition study,
which can be easily performed by a generic company like
Cipla Ltd.
From a purely scientific point of view, the selection of the
reference product, which is identical in formulation and
device, is the correct one. However, it is difficult to
understand why a CFC formulation is developed presently
when the CFC are almost completely replaced by HFA.
Finally, although a bronchodilator or bronchoprotection
model can be used to demonstrate therapeutic equivalence
of generic products of short-acting b2 agonists
12,14 because
they contain the same active substance, some might
think that in order to conclude similarity between salbuta-
mol and levosalbutamol it would be necessary to investigate
not only the bronchodilating effects but also the broncho-
protecting effects, since they are not the same chemical
entity.
This represents the personal opinion of the author and
does not necessarily represent the views or policy of the
Spanish Agency for Medicines and Health Care Products.
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